Health & Life Co., Ltd. AI Stock Analysis
Want to see TW:1781 full AI Analyst Report?
Health & Life Co., Ltd. (1781) AI Stock Analysis
Health & Life Co., Ltd.
(TPEx:1781)
The stock scores at the lowest possible level, reflecting a company in severe distress. The most significant factor is the deteriorating financial performance, marked by declining revenue, negative margins, and cash burn from operations. This is compounded by a bearish technical trend with the price below all key moving averages and weak momentum. The negative P/E ratio confirms a lack of earnings power. The company faces substantial fundamental and market-related risks.
Health & Life Co., Ltd. (1781) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 360.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 45.22K
- Price to Earnings (P/E)
- -6.7
- Beta (1Y)
- 0.42
- Revenue Growth
- -12.12%
- EPS Growth
- -17.27%
- Country
- TW
- Employees
- 120
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Health & Life Co., Ltd. Business Overview & Revenue Model
Company Description
Health & Life Co., Ltd. is a global provider of medical devices. Established in 1996 and headquartered in New Taipei City, Taiwan, the company specializes in developing and distributing solutions for critical health sectors, including cardiovascular...
Health & Life Co., Ltd. Financial Statement Overview
Summary
Financial health is critically weak. Revenue is in persistent decline, gross margins have collapsed to 13.2%, and the company is generating substantial net losses (-13.8% margin). Operating cash flow has turned negative, indicating the core business is burning cash. The only mitigating factor is a low debt-to-equity ratio of 0.12, but this is overshadowed by rapidly eroding shareholder equity.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 388.27M | 398.05M | 706.39M | 601.17M | 797.54M | 811.88M |
| Gross Profit | 51.10M | 70.12M | 147.74M | 93.11M | 97.72M | 45.76M |
| EBITDA | -34.66M | -46.70M | 55.63M | -7.84M | 11.85M | -63.05M |
| Net Income | -53.70M | -61.67M | 24.24M | -33.23M | -17.55M | -62.34M |
Balance Sheet | ||||||
| Total Assets | 688.11M | 723.13M | 817.26M | 710.79M | 799.76M | 776.39M |
| Cash, Cash Equivalents and Short-Term Investments | 283.42M | 247.94M | 277.35M | 151.05M | 156.98M | 200.32M |
| Total Debt | 34.18M | 196.97M | 214.14M | 113.60M | 189.45M | 134.81M |
| Total Liabilities | 405.83M | 402.56M | 424.21M | 375.42M | 427.18M | 398.22M |
| Stockholders Equity | 282.28M | 320.57M | 393.05M | 335.37M | 372.58M | 378.18M |
Cash Flow | ||||||
| Free Cash Flow | -15.30M | -5.01M | 30.14M | 76.82M | -93.02M | -145.04M |
| Operating Cash Flow | -8.64M | 3.18M | 33.35M | 84.91M | -80.69M | -131.15M |
| Investing Cash Flow | -6.80M | 41.96M | -89.81M | -8.78M | -10.32M | -16.02M |
| Financing Cash Flow | 26.85M | -21.91M | 128.68M | -74.67M | 25.91M | -91.10M |
Health & Life Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TW:1781, the sentiment is Negative. The current price of 7.60 is below the 20-day moving average (MA) of 8.78, below the 50-day MA of 9.56, and below the 200-day MA of 11.13, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 23.67 is Positive, neither overbought nor oversold. The STOCH value of 19.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TW:1781.
Health & Life Co., Ltd. Peers Comparison
Overall Rating
TW:178137Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 37Underperform | TWD 360.30M | -6.72 | ― | ― | -12.12% | -17.27% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1781 | Health & Life Co., Ltd. | 7.60 | -3.70 | -32.74% | |
| TW:4115 | Sunder Biomedical Tech. Co., Ltd. | 6.80 | -1.85 | -21.39% | |
| TW:4117 | General Biologicals Corp. | 7.00 | -5.05 | -41.91% | |
| TW:4186 | Taiwan Advance Bio-Pharmaceutical, Inc. | 6.00 | -5.75 | -48.94% | |
| TW:6549 | TaiwanJ Pharmaceuticals Co., Ltd. | 5.63 | -2.36 | -29.54% | |
| TW:6621 | Unipharma Co., Ltd. | 10.95 | -1.25 | -10.25% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026